Between Worlds Mike Walsh

I sat down with Pierre-Yves Calloc'h, Chief Digital Officer at Pernod Ricard, to discuss the company's journey in embracing AI, algorithms and automation to drive marketing effectiveness, sales performance, and consumer engagement. Pernod Ricard, known for its extensive portfolio of brands such as Absolut Vodka, Jameson, and Ballantine's, has been at the forefront of leveraging AI to make data-driven decisions and personalize consumer experiences.

Byron Reese, an acclaimed author, futurist, and entrepreneur shares his insights on the concept of ‘Agora’, a superorganism formed by the collective interactions of human beings. Drawing parallels complex adaptive systems like beehives, Reese argues that just as individual bees come together to create an entirely new organism with emergent properties, humans too form a higher-order entity through their differentiated roles and interactions.

What are the new challenges that generative AI is creating for copyright law? In this episode, I speak with Matt Hervey, the head of AI law at Gowling, to explore the legal intricacies surrounding the creation of content and ideas by large language models. In our discussion, Matt sheds light on the complex landscape of AI ownership, highlighting the differences in legal frameworks across various jurisdictions, such as the UK, EU, and US.

Mikko Hyppönen is a renowned Finnish cybersecurity expert and the Chief Research Officer at WithSecure. In our discussion, we delved into the rapidly evolving landscape of cybersecurity threats, particularly focusing on the impact of artificial intelligence and large language models

Dave Johnson is Chief Data and Artificial Intelligence Officer at Moderna, where he is responsible for all enterprise data capabilities from data engineering, data integration, data science, and software engineering. Johnson holds a PhD in Information Physics and has over 15 years of experience in software engineering and data science. He has spent more than a decade working exclusively in enterprise pharma and biotech companies.

- What if within the span of the next decade, we could live for an additional ten years or more? A hundred years ago, advances in infection control and public health led to a near doubling of the human life span. For us to achieve a similar feat today, we will need more than just scientific breakthroughs. Despite the rise of AI, powerful computation platforms and new discoveries in genomics, there is still a gap between everyday medical practice and technological innovation.